摘要
目的 探讨血小板糖蛋白IIb/IIIa拮抗剂 0替洛非班对不稳定性心绞痛患者血小板聚集率的影响。方法 2 0 0 2年 1月～ 12月间 ,入选既往有胸痛发作病史 ,近 1周内胸痛发作次数≥ 2次 ,持续 5min以上 ,伴随ST段水平性或下斜性压低≥ 1mm的不稳定性心绞痛患者 ,持续静脉输注糖蛋白IIb/IIIa拮抗剂替洛非班4 .5d ,负荷量 0 .4 μg/ (kg·min) ,维持量 0 .1μg/ (kg·min) ,检测治疗前后患者的血小板聚集率。 结果 糖蛋白IIb/IIIa拮抗剂应用前后 ,患者血小板聚集率平均聚集率分别为 (5 7.4± 2 1.7) %和 (4 5 .3± 2 6 .2 ) % ,两者间有显著性差异 (P <0 .0 5 )。结论 替洛非班可有效降低不稳定性心绞痛患者的血小板聚集率 ,对不稳定性心绞痛患者的治疗有重要意义。
Objective Investigating the influence of aggregation of platelet with intra-veinal glycoprotein of platelet IIb/ IIIa inhibitor dosage and the clinical effect. Methods From Jan 2002 to Dec 2002 , we choose patients with chest pain history,attack times≥ 2 and lasting 5min in recent 1 week,and whose ST segment≥1mm,and used drop pump to perfuse glycoprotein of platelet IIb/ IIIa inhibitor Trofiban of which load dose was 0.4μg/(kg· min)and maintaining dose was 0.1μg/(kg·min)through vein for 4.5 days. Before and after treating, we measured aggregation of platelet. Results After application of glycoprotein of platelet IIb/ IIIa inhibitor, the significant change has taken place on aggregation of platelet (57.4±21.7% vs 45.3±26.2%, P<0.05). Conclusion Glycoprotein of platelet IIb/ IIIa inhibitor may affect aggregation of platelet obviously and are effective in treating acute coronary syndrome.
出处
《医药论坛杂志》
2004年第10期13-14,共2页
Journal of Medical Forum
